Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
Primary result · Primary end point eventResult — go to the resultHazard ratio 0.65 95% CI 0.44–0.96Authors' conclusion
Among patients with T2D and a recent myocardial infarction, colchicine, 0.5 mg daily, leads to a large reduction of cardiovascular events. These results support the conduct of the COLCOT-T2D trial in primary prevention.
Study context
- Population
- Patients with T2D and recent MI (within 30 days)T2D subgroup
- Participants
- 959 patients
- Comparison
- Colchicine 0.5 mg daily vs placebo
- Primary endpoint
- Primary end point event
- Follow-up
- Median 22.6 months
Methodological detailsrandomized, double-blinded, placebo-controlled, prespecified T2D analysis
- Randomized
- Double-blinded
- Placebo-controlled
- Prespecified T2D analysis
Primary result
As reported in the abstract
median 22.6 months
Hazard ratio
0.65
95% CI 0.44–0.96
P = 0.03
By group
Colchicinevs Placebo
HR 0.65 (95% CI 0.44–0.96); P = 0.03
Safety
Nausea
P = 0.03
Pneumonia
P = 0.008
Original publication
Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. Published 5 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →